What is the current stock price of Orexo AB (publ) (ORXOY)?

As of the latest market data, Orexo AB (publ) (ORXOY) is trading at $2.80. The stock has seen a loss of -5.41% today.

Does Orexo AB (publ) (ORXOY) pay a dividend?

Based on current data, Orexo AB (publ) does not have a confirmed active dividend policy.

What is the market cap of Orexo AB (publ)?

The current market capitalization of Orexo AB (publ) (ORXOY) is approximately unavailable.

ORXOY

Orexo AB (publ)·Healthcare

2.80

5.405%(−0.16)

Market Open

Last Updated: — ET

52W L: $1.4852W H: $4.05

ORXOY NEWS

prnewswire.com

Mar 6

Invitation & Agenda: Orexo R&D Day on March 24

/PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026. The

prnewswire.com

Mar 6

Invitation & Agenda: Orexo R&D Day on March 24

UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026.

prnewswire.com

Mar 6

Orexo changes the organizational structure and management team to increase focus on development of new products

UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management team.

seekingalpha.com

Feb 5

Orexo AB (publ) (ORXOY) Q4 2025 Earnings Call Transcript

Company Profile

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

110

IPO Date

2018-03-15

Beta

0.96

Websitewww.orexo.com↗